lupin: Lupin’s test: Can the diversification into a tough diagnostics market break its new-ventures jinx?

Rajeev Sibal (left), president of India formulation business head, and Ravindra Kumar, head of Lupin Diagnostic.

Synopsis

The pharma company has launched this new venture, sniffing opportunity in the pandemic’s wake. But competition in this fragmented sector is also at an all-time high. Moreover, some of the company’s strategic bets from the past haven’t yielded results, and its returns have been falling, too. What are the chances that the latest diversification will fly amid these headwinds?

Medical diagnostics in the times of a pandemic is a lucrative business. People who are ill get tested, as do people with chronic conditions. Even healthy individuals get tested, as part of travel clearances or as a precaution. Leaving aside April to June of 2020, the pandemic has not only brought in volumes, but also improved the profitability of major diagnostics companies. Riding this wave, pharma company Lupin announced its foray into

BY

12 mins read, Last Updated:

Jan 21, 2022, 12:06 AM IST

• GIFT ARTICLE
• FONT SIZE

  AbcSmall

  AbcMedium

  AbcLarge

• SAVE
• PRINT
• COMMENT

Already an ET Prime Member? Sign In now

Continue reading with one of these options:

Limited Access

Free

Login to get access to some exclusive stories
& personalised newsletters

Login Now

Unlimited Access

Starting @ Rs120/month

Get access to exclusive stories, expert opinions &
in-depth stock reports

Subscribe Now

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Choose Payment Mode & Plan

–

–

–

Subscribe Now

(Credit card mandatory)

You can cancel your subscription anytime

–

–

–

Subscribe Now

(Pay Using Netbanking/UPI/Debit Card)

Netbanking, Credit & Debit Card

Subscribe with Google

₹399/month

Monthly
PLAN

Billed Amount ₹399

₹399

₹208/month

(Save 49%)

Yearly
PLAN

Billed Amount ₹2,499

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

₹399

₹150/month

(Save 63%)

2-Year
PLAN

Billed Amount ₹3,599

15
Days Trial
+Includes DocuBay and TimesPrime Membership.

Subscribe NowSubscribe with

Get ET Prime for just ₹2499 ₹1749/yr

Subscribe Now

Already a Member? Sign In now

Great New Year Sale

GET FLAT 30% OFF

On ET Prime & stay ahead of the rest in 2022

Get Offer

Why ?

• 

  Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

• 

  Stock analysis. Market Research. Industry Trends on 4000+ Stocks

• 

  Clean experience with
  Minimal Ads

• 

  Comment & Engage with ET Prime community

• 

  Exclusive invites to Virtual Events with Industry Leaders

• 

  A trusted team of Journalists & Analysts who can best filter signal from noise